Envoy Medical, Inc. 8-K

What Happened
Envoy Medical, Inc. announced in an 8‑K (filed Feb 27, 2026) that on Feb 23, 2026 it received a letter from the Nasdaq Listing Qualifications Hearings office confirming the company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2), consistent with the Nasdaq Hearing Panel’s letter dated Oct 23, 2025. The filing also states that, under Nasdaq Listing Rule 5815(d)(4)(B), the company will be subject to a discretionary Nasdaq panel monitor for a one‑year period beginning Feb 12, 2026. A press release dated Feb 24, 2026 was attached as Exhibit 99.1.

Key Details

• Letter from Nasdaq Listing Qualifications received by Envoy on Feb 23, 2026.
• Nasdaq confirmed compliance with Listing Rule 5550(b)(2) in line with the Hearing Panel’s Oct 23, 2025 letter.
• Envoy will be under a discretionary Nasdaq panel monitor for one year beginning Feb 12, 2026.
• Company issued a press release on Feb 24, 2026 (Exhibit 99.1) announcing these developments.

Why It Matters
This filing indicates Envoy addressed a previously identified Nasdaq listing deficiency and remains in compliance with the cited listing rule, avoiding delisting on that basis. The imposed one‑year discretionary monitor means Nasdaq will maintain closer oversight of the company’s compliance during that period, which investors should note as ongoing regulatory attention. Investors may want to read the attached press release and watch future filings for updates on compliance and any additional Nasdaq requirements.